Dual Antiviral Therapy for Persistent Coronavirus Disease 2019 and Associated Organizing Pneumonia in an Immunocompromised Host-Reference-Cited by-同舟云学术

Dual Antiviral Therapy for Persistent Coronavirus Disease 2019 and Associated Organizing Pneumonia in an Immunocompromised Host

Published:2022-10-25 Issue:5 Volume:76 Page:923-925
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Trottier Caitlin A¹^ORCID,Wong Beverly²,Kohli Rakhi¹³,Boomsma Cassidy³,Magro Francis⁴,Kher Sucharita²³,Anderlind Christina²³,Golan Yoav¹³

Affiliation:

1. Department of Medicine, Division of Geographic Medicine and Infectious Diseases , Boston, Massachusetts , USA

2. Department of Medicine, Division of Pulmonary and Critical Care, Tufts Medical Center , Boston, Massachusetts , USA

3. Department of Medicine, Tufts University School of Medicine , Boston, Massachusetts , USA

4. Department of Medicine, Division of Infectious Diseases, Lowell General Hospital , Lowell, Massachusetts , USA

Abstract

AbstractThe management of patients with prolonged viral shedding and coronavirus disease 2019 symptoms remains unclear. Combining antivirals, as practiced in other infections, is theoretically advantageous. We present a case of persistent, symptomatic severe acute respiratory syndrome coronavirus 2 infection and associated organizing pneumonia that was successfully treated with an extended course of combination antiviral therapy.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac847/47107017/ciac847.pdf

Reference12 articles.

1. Persistence and evolution of SARS-CoV-2 in an immunocompromised host;Choi;N Engl J Med,2020

2. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer;Aydillo;N Engl J Med,2020

3. Persistent severe acute respiratory syndrome coronavirus 2 infection in immunocompromised host displaying treatment induced viral evolution;Monrad;Open Forum Infect Dis,2021

4. Extended remdesivir infusion for persistent coronavirus disease 2019 infection;Martinez;Open Forum Infect Dis,2022

5. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy;Helleberg;J Infect Dis,2020

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of persistent coronavirus disease 2019 (COVID-19) in a B cell acute lymphoblastic leukemia patient with using nirmatrelvir/ritonavir extended course: A case report;Journal of Infection and Public Health;2024-10

2. Antiviral therapy for COVID-19;COVID-19: An Update;2024-09-01

3. Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management;Clinical Microbiology and Infection;2024-08

4. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma;Journal of Infection and Chemotherapy;2024-08

5. Persistent SARS-CoV-2 infection: significance and implications;The Lancet Infectious Diseases;2024-07